The global ulcerated necrobiosis lipoidica management market is anticipated to attain an impressive valuation of US$ 4.4 billion in 2023 and is projected to reach US$ 7.9 billion by 2033, trailing a CAGR of 6.03% during the forecast period.
Growing incidences of diabetes as well as shift in urbanization and sedentary lifestyle, are key factors expected to fuel the Ulcerated Necrobiosis Lipoidica Management. Furthermore, improvements in technology in the field of diabetes as well as surging diabetic population is anticipated to propel market growth during the forecast period.
Growing prevalence of risk factors, for example diabetes, cancer, alcoholism, rising geriatric population, surging rate of bacterial infection and growing importance of research on diagnosis and treatment of rare diseases are some major factors that are anticipated to increase the growth and demand of the Global Necrotizing Fasciitis Market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.4 billion |
| Anticipated Forecast Value (2033) | US$ 7.9 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 6.03% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for Ulcerated Necrobiosis Lipoidica was worth US$ 3.5 billion in 2018, while growing at a CAGR of 4.68% during the historical period. Several factors like awareness in wellness and health, the diagnostic and pathology segment are getting a stronghold in the developing countries nowadays which is expected to fuel Ulcerated Necrobiosis Lipoidica treatment market. Moreover, the research and development activities in the field of emerging novel therapeutics is increasing the efficacy of medicine as well as treatment which is presenting growth opportunities for the targeted industry.
On the other hand, selling campaigns started by the global players is propelling the market upwards. Also, increasing focus by government organizations and private agencies such as WHO and pharmaceutical companies to create awareness of necrobiosis Lipoidica will benefit the market in the coming years.
In Addition, PCS499 is an oral emerging drug that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental). It is currently being investigated for the treatment of Ulcerated Necrobiosis Lipoidica. PCS499 and its metabolites work by acting upon multiple pharmacological targets that are important in several conditions. The Food and drug administration granted Orphan Drug Designation for PCS499 for the treatment of necrobiosis lipoidica and seven years of Unites states exclusivity on the FDA approval. Considering these factors and new developments, the revenue growth of Ulcerated Necrobiosis Lipoidica treatment is projected to be worth US$ 7.9 billion by end of the forecast period, while exhibiting a CAGR of 6.03%.
Launch of new drugs expected to drive market growth
The increasing demand for effective cure indicated for necrobiosis lipoidica infections as current standard cure for these infections also involves surgical debridgement unfortunately leading to amputations which is expected to fuel market growth. To prevent loss of limb or fatal outcome, the need for novel therapies in Necrobiosis infections rises, which is anticipated to propel market growth during the forecast period. Also rapid discovery of novel therapy like hyperbaric oxygen therapy is further anticipated to augment revenue growth in this market during the forecast period.
Growth in advanced diagnostic techniques for diagnosis of necrobiosis lipoidica such as magnetic resonance imaging is contributing to market expansion of necrobiosis lipoidica treatment market. Furthermore, approval and launch of new medicines by leading companies is the other important factor augmenting growth of this market.
A vast number of drug candidates are in different stages of clinical trials in the United States and Europe. The expected launch and commercialization of these products is anticipated to fuel the global ulcerated necrobiosis lipoidica treatment market during the forecast period. Also, rising healthcare expenditure fuels demand for research and development of biologics and biosimilars for treatment of necrobiosis lipoidica which is expected to propel market growth in the forecast period.
Principal Consultant
High cost and improper diagnosis restraining market expansion
Improver diagnosis of Ulcerated necrobiosis lipoidica disease is anticipated to challenge growth of this market, since initial symptoms are often mistaken for flu. High cost of treatment is also expected to hold back expansion of this market during the projected period.
North America to dominate the market with maximum share
North America is anticipated to dominate the market of Ulcerated necrobiosis lipoidica treatment by accounting for 41% market share by end of the forecast period. The market in this region is projected to be worth more than USD 3.2 billion by 2033. The growth is attributable to increasing prevalence of necrobiosis lipoidica condition in this region. A study was conducted titled “ Development of a new critical pathway for treatment of acute skin structure infections under the clinical development for the drug ‘Dalbavancin’ from the allergen pharmaceutical in the unites states. These developments in this region will open up new opportunities for market expansion of Necrobiosis lipoidica.
On the other hand, an estimated 34.2 million people have diabetes (10.5 % of the United States population. Therefore, the risk of necrobiosis lipoidica diabectorum is anticipated to rise in the region and it will lead to market expansion.
The increasing product pipeline and product approval by regulatory authorities are anticipated to boost the market during the forecast period. For example, in July 2021, the Food and Drug Administration expanded the approval of Dalvance to include treatment of acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms in pediatric patients. The treatment was only approved for adults 18 and older few years ago. In addition, in January 2022, Paladin Labs Inc., which is a subsidiary of Endo International plc developed and launched Xydalba (dalbavancin for injection), a 30-minute intravenous therapy in Canada for acute bacterial skin and skin structure infections that can be administered as a single- or two-dose regimen. These factors and developments will lead to market expansion in this region.
Asia Pacific market driving growth with fastest CAGR
The market of ulcerated necrobiosis lipoidica in Asia Pacific is estimated to witness fastest CAGR of 6.5% during the forecast period. This region is anticipated to possess 32.8% market share by end of 2033. Furthermore, market in this region will be worth more than US$ 2.59 billion by end of the projected period. The growth in this region is attributed to rising prevalence of acute skin related and skin structure related disorders.
Furthermore, growing awareness, significant rise in healthcare spending and increasing frequency of Necrobiosis Lipoidica Diabeticorum in this region. Moreover, Asia Pacific is an emerging market owing to the increase in point of care approach in health and care. Also, growing number of hospitals in India and China makes a promising market for the treatment market across the globe.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
UVA1 Phototherapy segment driving growth with fastest CAGR
By treatment, UVA1 phototherapy is anticipated to reflect fastest CAGR of 6.8% during the forecast period. This segment is projected to account for 31% market share by end of the projected period. The growth is attributable to better efficacy offered by this therapy and growing prevalence of clinical trials on this method. The treatment by Phototherapy is treated as the first line therapy by the healthcare professionals.
Furthermore, this therapy has been proved to be the most successful therapy than methyl aminolevulinate (MAL)-photodynamic therapy, aminolevulinic acid-PDT, and psoralen plus ultraviolet-A (PUVA) with very less side-effects. Thus, these factors will lead to the fastest growth Ultraviolet A 1 phototherapy for the treatment of ulcerated necrobiosis lipoidica during the forecast period.
Hospitals pushing growth with significant market share
The hospital segment dominated the market of Ulcerated Necrobiosis Lipoidica in 2022, with a market share of 59% . This segment is anticipated to retain its dominance by accounting for more than 71% market share by end of the forecast period. This segment will grow with a CAGR of 5.7% during the projected period. The factors that can be attributed to growth of this segment such as ease of interaction with prescribers and other health professionals are fuelling the demand for this segment.
Start-ups help in understanding the growth opportunities and prospects in any industry. These new businesses have the potential to generate high returns which directly benefits the growth of any industry. These start-ups are naturally more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to volatile market conditions. Some of the start-ups that will augment the expansion of Ulcerated Necrobiosis Lipoidica Management Market are:
The ulcerated necrobiosis lipoidica management market is intensely competitive and consists of numerous key market players. These key players are developing novel delivery systems for treating ulcerated necrobiosis lipoidica. This is estimated to fuel Ulcerated Necrobiosis Lipoidica Management Market. The key players in this market are: Astellas Pharma, Vibcare Pharma, Pfizer, Manus Aktteva Biopharma LLP, Mylan Pharmaceuticals Inc., Upsher-Smith Laboratories, Novartis, Sanofi, Merck, GlaxoSmithKline
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to strengthen their product portfolio. This is anticipated to fuel the global Uulcerated necrobiosis lipoidica management market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 4.4 billion |
| Market Value in 2033 | US$ 7.9 billion |
| Growth Rate | CAGR of 6.03 % from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global Ulcerated Necrobiosis Lipoidica Management Market to expand at 6.03% value CAGR by 2033.
The global Ulcerated Necrobiosis Lipoidica Management Market is expected to garner a market value of US$ 7.9 billion by 2033.
FMI has projected North America to be one of the most profitable regions for Ulcerated Necrobiosis Lipoidica Management Market.
Asia Pacific is anticipated to grow fastest during the forecast period.
UVA1 Phototherapy is expected to dominate the market by treatment type during the forecast period
Hospitals are projected to lead the market with maximum share by end of the forecast period
The market value of Ulcerated Necrobiosis Lipoidica Management Market was worth US$ 3.5 billion in 2018.
The market in North America is projected to account for 41% market share by end of the forecast period.
1. Executive Summary | Ulcerated Necrobiosis Lipoidica Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Skin Grafting
5.3.2. Photodynamic Therapy
5.3.3. UVA1 Phototherapy
5.3.4. Topical Psoralen-UVA Therapy
5.3.5. Drugs
5.3.5.1. Antimalarial Agents
5.3.5.2. Antitubercular Agents
5.3.5.3. Immunosuppressive Agents
5.3.5.4. Hemorrheologic Agents
5.3.5.5. Fumaric Acid Esters
5.3.5.6. Calcineurin Inhibitors
5.3.5.7. Corticosteroids
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The USA
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom (UK)
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End User
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End User
13.6. UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End User
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End User
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End User
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End User
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End User
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End User
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End User
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End User
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Astellas Pharma
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Vibcare Pharma
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Pfizer
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Manus Aktteva Biopharma LLP
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Mylan Pharmaceuticals Inc.
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Upsher-Smith Laboratories
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Novartis
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Sanofi
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Merck
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. GlaxoSmithKline.
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Ulcerated Necrobiosis Lipoidica Management Market
